Given leukocytosis with neutrophilia and eosinophilia, macrocytosis, impaired renal function (stage 3 chronic kidney disease, CKD), elevated fasting glucose, dyslipidemia, and vitamin D deficiency, what is the most likely diagnosis and how should it be managed?

Stage 3 Chronic Kidney Disease with Prediabetes, Dyslipidemia, and Vitamin D Deficiency

You have Stage 3 chronic kidney disease (CKD) with prediabetes, dyslipidemia, and vitamin D deficiency—a constellation requiring immediate lifestyle modification, blood pressure optimization, and targeted supplementation to prevent progression to kidney failure and reduce cardiovascular risk.

Primary Diagnoses

Your laboratory results reveal:

• Stage 3a CKD (GFR 64.8 mL/min/1.73 m²) 1
• Prediabetes (fasting glucose 139 mg/dL)
• Dyslipidemia (low HDL 42 mg/dL, elevated LDL 114 mg/dL)
• Vitamin D deficiency (25-OH vitamin D 24 ng/mL)
• Macrocytic anemia (MCV 104.8 fL, hemoglobin 13.5 g/dL)
• Leukocytosis with neutrophilia (WBC 13.73, neutrophils 75.7%)
• Possible eosinophilia (if "esophageal 7.4" refers to eosinophils at 7.4%)

Critical Management Algorithm

1. Immediate Actions for CKD Stage 3a

Blood Pressure Control (Primary Priority)

• Target BP <130/80 mmHg 1
• Start ACE inhibitor or ARB if you develop albuminuria (need UACR testing) 1
• These medications slow CKD progression and reduce cardiovascular events

Obtain Missing Critical Tests

• Urine albumin-to-creatinine ratio (UACR) - essential for staging and treatment decisions 1
• Repeat serum creatinine to confirm GFR stability
• Complete blood count with differential to clarify the "esophageal" value (likely eosinophils)

2. Glycemic Management

Prediabetes Intervention

• Lifestyle modification is first-line: Mediterranean diet, 150 minutes/week moderate exercise, 5-7% weight loss if overweight 2
• Consider metformin if lifestyle fails and you have additional risk factors (obesity, family history) 2
• Metformin is safe with GFR >45 mL/min/1.73 m² but requires monitoring 3
• Target fasting glucose <100 mg/dL, HbA1c <5.7%

If diabetes develops (repeat glucose ≥126 mg/dL or HbA1c ≥6.5%):

• SGLT2 inhibitors are preferred for CKD protection even at Stage 3a 1, 3, 1
• These reduce kidney disease progression, cardiovascular events, and mortality independent of glucose lowering

3. Dyslipidemia Treatment

Statin Therapy Indicated

• Your LDL 114 mg/dL with CKD Stage 3 qualifies you for moderate-intensity statin therapy 4
• Start atorvastatin 10-20 mg daily or rosuvastatin 5-10 mg daily
• Target LDL <100 mg/dL (ideally <70 mg/dL given CKD cardiovascular risk)
• Low HDL (42 mg/dL) will improve with lifestyle modification and glycemic control

4. Vitamin D Replacement

Nutritional Vitamin D Deficiency Protocol

• Your level of 24 ng/mL is deficient (target >30 ng/mL) 5, 6
• Ergocalciferol (vitamin D2) 50,000 IU weekly for 8-12 weeks, then monthly maintenance 6
• Alternative: Cholecalciferol (vitamin D3) 2,000-4,000 IU daily (preferred formulation) 7, 8
• Recheck 25-OH vitamin D level in 3 months
• Do NOT use calcitriol or active vitamin D analogs—these are reserved for Stage 4-5 CKD with secondary hyperparathyroidism 6, 8

5. Macrocytic Anemia Evaluation

Your MCV 104.8 fL requires investigation 9, 10:

• Vitamin B12 is low-normal at 277 pg/mL (optimal >400 pg/mL)
• Folate >24 ng/mL is adequate
• Start vitamin B12 supplementation 1,000 mcg daily orally or consider B12 injections if absorption suspected 9
• Recheck CBC in 8-12 weeks
• Rule out hypothyroidism (TSH), alcohol use, and medication effects

6. Dietary Modifications for CKD Stage 3

Protein Restriction

• Limit protein to 0.8 g/kg/day (same as general population) 1
• Avoid high-protein diets that accelerate CKD progression

Sodium and Potassium

• Sodium <2 g/day to control blood pressure 5
• Monitor potassium levels (yours is normal at present)
• Avoid NSAIDs, which worsen kidney function

Phosphorus Monitoring

• Not yet critical at Stage 3a but will become important if progression occurs

7. Leukocytosis and Eosinophilia Investigation

WBC 13.73 with neutrophilia (75.7%) and possible eosinophilia (7.4%):

• Rule out infection, inflammation, medication reaction
• If eosinophils truly elevated (>0.5 x 10⁹/L), consider parasitic infection, allergic conditions, or drug reaction
• Repeat CBC in 2-4 weeks to assess persistence

8. Nephrology Referral Criteria

Refer to nephrologist if 1:

• UACR ≥300 mg/g (macroalbuminuria)
• GFR declines to <45 mL/min/1.73 m² (Stage 3b)
• GFR drops >5 mL/min/year
• Rapidly increasing albuminuria
• Active urinary sediment or hematuria

9. Monitoring Schedule

Every 3-6 months 1, 11:

• Serum creatinine and eGFR
• UACR
• Electrolytes (sodium, potassium, bicarbonate)
• Lipid panel
• HbA1c or fasting glucose

Annually:

• Complete blood count
• Calcium, phosphorus, PTH (when GFR <45)
• 25-OH vitamin D level
• Comprehensive eye exam (diabetic retinopathy screening) 2

Common Pitfalls to Avoid

1. Do not ignore albuminuria testing—UACR is essential for risk stratification and determines ACE/ARB indication 1
2. Do not use active vitamin D (calcitriol) for simple vitamin D deficiency—this causes hypercalcemia and is only for advanced CKD with hyperparathyroidism 6, 8
3. Do not restrict protein below 0.8 g/kg/day—excessive restriction causes malnutrition without additional benefit at Stage 3 1
4. Do not delay statin therapy—CKD dramatically increases cardiovascular risk, which is the leading cause of death 4
5. Do not use metformin if GFR drops below 30 mL/min/1.73 m²—adjust or discontinue based on kidney function 3

Prognosis and Goals

Your Stage 3a CKD is potentially stabilizable with aggressive risk factor modification. The primary goals are:

• Prevent progression to Stage 4-5 CKD requiring dialysis
• Reduce cardiovascular mortality risk (the most common cause of death in CKD) 1
• Maintain quality of life through symptom management and complication prevention

With optimal management, many patients with Stage 3a CKD never progress to kidney failure. The key is early intervention, strict blood pressure control, diabetes prevention/management, and regular monitoring 1.